Defense Stock Domin...
Health Care: Drugs
Neuralstem Inc. (CUR: AMEX)
$1.44 0.01 | 0.70%
05/23/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -10.12M | -12.52M | -18.39M | -10.36M |
| Operating Gains/Losses | 0.00 | -161.81K | 1.35M | -83.35K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 231.04K | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 87.75K | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -644.02K | 888.25K | 213.57K | 243.66K |
| (Decrease) Increase In Other Current Liabilities | 54.87K | 129.44K | -67.61K | 423.71K |
| (Increase) Decrease In Other Working Capital | 15.83K | -14.52K | -327.29K | -2.74K |
| Other Non-Cash Items | 1.61M | 3.33M | 7.15M | 4.56M |
| Net Cash From Continuing Operations | -8.48M | -8.10M | -9.98M | -5.14M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -8.48M | -8.10M | -9.98M | -5.14M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -254.86K | -480.85K | -332.68K | -210.78K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -254.86K | -480.85K | -332.68K | -210.78K |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 13.89M | 1.67M | 17.27M | 2.76M |
| Repayment of Long-Term Debt | -65.09K | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 13.82M | 1.67M | 17.27M | 2.76M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 5.09M | -6.91M | 6.95M | -2.59M |
Portfolios with CUR
- Portfolio NameUser Type
- Userdennis diamonds
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- Usermine
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserBio
- Userjustin
- ContributorBreakout Stocks Of The Week...
Latest CUR Headlines from TheStreet
- 4 Biotech Stocks Under $10 Moving Higher 11.27.12 | 02:11 pm
- 4 Biotech Stocks Under $10 Moving Higher 10.05.12 | 08:10 am
- Stocks Close Week Higher on QE3 Confidence 09.14.12 | 05:09 pm
- 5 Stocks Under $10 Setting Up to Break Out 09.13.12 | 12:09 pm
- 5 Stocks Poised for Big Breakouts 08.31.12 | 01:08 pm
- 9 Biotech Penny Stocks to Buy 08.31.10 | 10:08 am
- Interstate Hotel, Neuralstem: Midday Volume Plays 12.18.09 | 01:12 pm
- Four Must-See Charts: Stem Cell Stocks 07.02.09 | 03:07 pm
- Stem cell firms jump on Obama policy plans 03.06.09 | 06:03 pm
- Wednesday's Health Winners & Losers 09.19.07 | 04:09 pm
Press Releases for CUR
- Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania - PR Newswire 05.20.13 | 09:05 am
- Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In London - PR Newswire 05.16.13 | 09:05 am
- DiagnoCure Announces Presentation On Previstage GCC At The 2013 ASCO Annual Meeting - PR Newswire 05.16.13 | 07:05 am
- Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress - PR Newswire 05.13.13 | 09:05 am
- Neuralstem ALS Trial Investigator And Patient On Sirius XM - PR Newswire 05.08.13 | 09:05 am
- Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting - PR Newswire 04.29.13 | 11:04 am
- DiagnoCure's Update Presentation During The Annual And Special Meeting Of Shareholders - PR Newswire 04.29.13 | 07:04 am
- Neuralstem And The National Football League Alumni Association Announce Initiative On Brain Injury Treatment - PR Newswire 04.24.13 | 09:04 am
- FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder - PR Newswire 04.22.13 | 09:04 am
- Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention - PR Newswire 04.18.13 | 09:04 am
Partner Headlines for CUR
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned - Seeking Alpha 12.16.12 | 08:12 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- 4 Biotechs That Just Got Mauled By Bears - Seeking Alpha 10.10.12 | 09:10 am
- Morning Market Movers - Benzinga 10.04.12 | 09:10 am
- Dr. Eva Feldman, Principal Investigator, To Update Interim Data On Neuralstem ALS Trial - Benzinga 10.04.12 | 09:10 am
- Neuralstem Grants First Licenses for CNS Therapy Surgical Devices - Benzinga 09.06.12 | 09:09 am
- ALS Patient's Survival is "One of the Most Powerful Stories" Ever Reported - Benzinga 08.27.12 | 01:08 pm
- End-of-Day Market Summary for November 23, 2011 - Benzinga 11.23.11 | 04:11 pm
